Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases

Holborough-Kerkvliet MD, Kroos S, van de Wetering R, Toes REM (2023) Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases. Immunol Lett 259:37-45. doi: 10.1016/j.imlet.2023.05.005 PMID: 37209914

Objective: Using cyclic citrullinated peptide (CCP) conjugated to CNBz and saporin to eliminate autoreactive B cells, as a treatment for rheumatoid arthritis (RA).

Summary: Joint damage in the body creates cyclic citrullinated peptide (CCP) which is a marker of Rheumatoid arthritis (RA). The CCP active site that autoantibodies target is blocked with CNBz and the whole complex is conjugated with saporin allowing cytotoxicity directed towards autoreactive B cells, a damaging element of RA, without being reactive with CCP-targeted autoantibodies.

Related Products: Saporin (Cat. #PR-01)

See Also:

• Lelieveldt LPWM et al. Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells. Mol Pharm 15(12):5565-5573, 2018.